Fig. 2From: Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjectsArithmetic mean plasma concentration–time profiles of lucerastat in healthy subjects on Day 7 after multiple-dose administration of 200, 500, and 1000 mg lucerastat b.i.d. (intakes separated by 12 h, linear and semilogarithmic scales, 0–48 h). (Per–protocol set)Back to article page